{"id":62638,"date":"2026-04-25T01:07:04","date_gmt":"2026-04-24T23:07:04","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/04\/25\/e-cadherin-expression-promotes-tumor-growth-via-klrg1-dependent-pathways\/"},"modified":"2026-04-25T01:07:04","modified_gmt":"2026-04-24T23:07:04","slug":"e-cadherin-expression-promotes-tumor-growth-via-klrg1-dependent-pathways","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/04\/25\/e-cadherin-expression-promotes-tumor-growth-via-klrg1-dependent-pathways\/","title":{"rendered":"E-cadherin expression promotes tumor growth via KLRG1-dependent pathways"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2026 Apr 15;215(4):vkag046. doi: 10.1093\/jimmun\/vkag046.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Transformed cells frequently adapt to immune pressure by modulating expression of ligands for PD-1 and CTLA-4. Despite the success of therapies targeting these interactions, only a minority of patients experience a clinical response, highlighting the critical need for alternative targets. Prior work from our group showed that the inhibitory receptor KLRG1 binds to tumor-derived E-cadherin. However, the therapeutic potential of targeting KLRG1 signaling remains incompletely understood. To address this, we generated a library of cancer cell lines engineered to express varying levels of E-cadherin. Across multiple models, we demonstrate that E-cadherin expression renders tumors more aggressive in vivo. Using an RMA-S cell line possessing a mutated E-cadherin that abrogates KLRG1 binding while preserving cadherin homotypic interactions, we demonstrate that the protumor effect of E-cadherin expression is largely mediated by KLRG1. To further dissect the cellular targets of KLRG1 signaling, we generated KLRG1fl\/fl mice and performed lineage-specific deletion. Surprisingly, we discovered that KLRG1 expression on CD8+ T cells, rather than on natural killer cells, impairs the immune control of B16-F10 E-cadherin+ tumors. Taken together, these results reveal an underappreciated protumor role for E-cadherin and highlight KLRG1 as a promising target for future checkpoint blockade strategies, particularly in tumors retaining epithelial features.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030532\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20260424190704&amp;v=2.19.0.post6+133c1fe\">42030532<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkag046\">10.1093\/jimmun\/vkag046<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2026 Apr 15;215(4):vkag046. doi: 10.1093\/jimmun\/vkag046. ABSTRACT Transformed cells frequently adapt to immune pressure by modulating expression of ligands for PD-1 and CTLA-4. Despite the success of therapies targeting these interactions, only a minority of patients experience a clinical response, highlighting the critical need for alternative targets. Prior work from our group showed that &#8230; <a title=\"E-cadherin expression promotes tumor growth via KLRG1-dependent pathways\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/25\/e-cadherin-expression-promotes-tumor-growth-via-klrg1-dependent-pathways\/\" aria-label=\"Read more about E-cadherin expression promotes tumor growth via KLRG1-dependent pathways\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-62638","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/62638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=62638"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/62638\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=62638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=62638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=62638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}